All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 10 May 2018, a study was published in Haematologica assessing the use of rituximab and bendamustine in combination as front line therapy for frail elderly patients with diffuse large B-cell lymphoma (DLBCL). The paper was published by Sergio Storti, Universita Cattolica Sacro Cuore Campbasso, Italy, and colleagues from the Fondazione Italiana Linfomi (Italian Lymphoma Foundation).
The phase II study (NCT01990144) evaluated the efficacy and safety of the combination of bendamustine and rituximab in patients with previously untreated DLBCL. Patients were defined as ‘frail’ in-line with the Comprehensive Geriatric Assessment (CGA). The study addressed an unmet need in this patient population for the treatment of frail elderly patients who are unable to be treated with the standard R-CHOP therapy.
The authors concluded that they found the combination of bendamustine and rituximab to be a good treatment option showing “promising activity” for elderly frail patients with DLBCL. They noted that a larger sample size would be needed to further assess the PFS and OS in this treatment population.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox